Factors associated with major adverse cardiovascular events at 6 months in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention
Main Article Content
Abstract
A combined retrospective and prospective cohort study was conducted on 240 patients with non–ST-segment elevation myocardial infarction (NSTEMI), undergoing percutaneous coronary intervention (PCI) to determine the 6-month rate of major adverse cardiovascular events (MACE) and associated factors. The mean age was 69.4 ± 12.1 years old, and 62.1% were male. The 6-month MACE rate was 29.2%, with rehospitalization for heart failure being the most frequent event (10.0%), followed by in-hospital mortality (7.9%) and recurrent myocardial infarction after discharge (5.4%). Univariable logistic regression identified associations between MACE and age, comorbidities, Killip class, renal function, NT-proBNP, left ventricular ejection fraction, GRACE score, and left main coronary artery disease (LMCAD). In multivariable analysis, dyslipidemia (OR = 3.13; 95% CI: 1.58 - 6.20), Killip class ≥ II at admission (OR = 4.33; 95% CI: 2.19 - 8.56), and LMCAD (OR = 4.62; 95% CI: 2.17 - 9.85) remained independently associated with MACE. These findings indicate that patients with NSTEMI undergoing PCI remain at a high risk of adverse events within 6 months, particularly those with high clinical and anatomical risk profiles, underscoring the value of early risk stratification in post-procedural management and follow-up.
Article Details
Keywords
Killip classification, left main coronary artery disease, major adverse cardiovascular events, non-ST-segment elevation myocardial infarction, percutaneous coronary intervention
References
2. Darling CE, Fisher KA, McManus DD, et al. Survival after hospital discharge for ST-segment elevation and non-ST-segment elevation acute myocardial infarction: A Population-based study. Clin Epidemiol. 2013; 5(1): 229-236. doi:10.2147/CLEP.S45646.
3. Vora AN, Wang TY, Hellkamp AS, et al. Differences in short- and long-term outcomes among older patients with ST-elevation versus non-ST-elevation myocardial infarction with angiographically proven coronary artery disease. Circ Cardiovasc Qual Outcomes. 2016; 9(5): 513-522. doi:10.1161/CIRCOUTCOMES.115.002312.
4. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44(38): 3720-3826. doi:10.1093/eurheartj/ehad191.
5. Ismail SR, Mohammad MSF, Butterworth AS, et al. Risk Factors of Secondary Cardiovascular Events in a Multi-Ethnic Asian Population with Acute Myocardial Infarction: A Retrospective Cohort Study from Malaysia. J Cardiovasc Dev Dis. 2023; 10(6): 250. doi:10.3390/jcdd10060250.
6. Lu Y, Wang Y, Zhou B. Predicting long-term prognosis after percutaneous coronary intervention in patients with acute coronary syndromes: a prospective nested case-control analysis for county-level health services. Front Cardiovasc Med. 2023; 10: 1297527. doi:10.3389/fcvm.2023.1297527.
7. Đặng Đức Minh, Phạm Nguyên Sơn, Nguyễn Tiến Dũng. Giá trị tiên lượng các biến cố tim mạch của hs-troponin T, NT-proBNP và hs-CRP, thang điểm TIMI và GRACE ở bệnh nhân nhồi máu cơ tim cấp không ST chênh lên được can thiệp động mạch vành qua da thì đầu. Tạp chí Y Dược lâm sàng 108. 2020; 15(6): 14-20.
8. Trịnh Việt Hà, Nguyễn Thị Thu Hoài, Lê Thị Ngà, Đỗ Doãn Lợi. Giá trị tiên lượng của sức căng cơ tim ở bệnh nhân hội chứng vành cấp không ST chênh lên được can thiệp động mạch vành qua da. Tạp chí Tim mạch học Việt Nam. 2021; 94+95: 197-204.
9. Le Van Duy, Ho Anh Binh, Tran Quoc Bao. The rate of major adverse cardiovascular events (MACE) in patients with acute coronary syndrome undergoing percutaneous coronary intervention. J Clin Med Hue Cent Hosp. 2024; (95): 84-91. doi:10.38103/jcmhch.95.13.
10. Trần Nguyễn Phương Hải, Hoàng Văn Sỹ. Giá trị tiên đoán kết cục tim mạch của non-high-density cholesterol ở bệnh nhân hội chứng mạch vành cấp không st chênh lên. Tạp chí y học Việt Nam. 2024; 535(1B): 47-51.
11. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019; 40(3): 237-269. doi:10.1093/eurheartj/ehy462.
12. Zhao LH, Liu Y, Xiao JY, et al. Prognostic Value of Metabolic Syndrome in Patients With Non-ST Elevated Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Front Cardiovasc Med. 2022; 9: 912999. doi:10.3389/fcvm.2022.912999.
13. Stanojkovic A, Mrdovic I, Tosic I, et al. Prognostic Value of the RISK-PCI Score in Patients with Non-ST-Segment Elevation Acute Myocardial Infarction. J Clin Med. 2025; 14(8): 2727. doi:10.3390/jcm14082727.
14. Okkonen M, Havulinna AS, Ukkola O, et al. Risk factors for major adverse cardiovascular events after the first acute coronary syndrome. Ann Med. 2021; 53(1): 817-823. doi:10.1080/07853890.2021.1924395.
15. Puymirat E, Simon T, Cayla G, et al. Acute myocardial infarction: Changes in patient characteristics, management, and 6-month outcomes over a period of 20 years in the FAST-MI program (French registry of acute ST-elevation or non-ST-elevation myocardial infarction) 1995 to 2015. Circulation. 2017; 136(20): 1908-1919. doi:10.1161/CIRCULATIONAHA.117.030798.
16. Jalali A, Hassanzadeh A, Najafi MS, et al. Predictors of major adverse cardiac and cerebrovascular events after percutaneous coronary intervention in older adults: a systematic review and meta-analysis. BMC Geriatr. 2024; 24(1): 1-12. doi:10.1186/s12877-024-04896-4.
17. Baumann AAW, Tavella R, Air TM, et al. Prevalence and real-world management of NSTEMI with multivessel disease. Cardiovasc Diagn Ther. 2022; 12(1): 1-11. doi:10.21037/cdt-21-518.